1. Introduction {#sec1-toxins-08-00201}
===============

Bladder pain syndrome/interstitial cystitis (BPS/IC) is a disease with clinical presentations of chronic pelvic/bladder pain, urinary frequency, and nocturia \[[@B1-toxins-08-00201],[@B2-toxins-08-00201]\]. In the United States, it is estimated that about 6.5% or eight million women aged ≥18 years could be diagnosed as BPS/IC \[[@B3-toxins-08-00201]\]. The possible mechanism of BPS/IC remains unclear, although several pathogeneses including neurogenic inflammation, autoimmune disorder, mast-cell activation and urothelial dysfunction \[[@B4-toxins-08-00201],[@B5-toxins-08-00201],[@B6-toxins-08-00201],[@B7-toxins-08-00201],[@B8-toxins-08-00201]\] have been reported. Cystoscopy with hydrodistention under anesthesia and biopsy if indicated is the first choice for diagnosis, classification and treatment \[[@B1-toxins-08-00201],[@B2-toxins-08-00201],[@B9-toxins-08-00201]\]. Among patients with BPS/IC, mucosal fissure with bleeding and Hunner's ulcer are common findings after hydrodistension. According to guidelines of European Association of Urology, the available treatment options for patients with BPS/IC included the oral pentosan polysulfate sodium and intravesical Dimethyl sulfoxide (DMSO) which are both FDA-approved drugs \[[@B1-toxins-08-00201],[@B2-toxins-08-00201]\]. Botulinum neurotoxins (BoNTs), which are produced by the bacterium Clostridium botulinum, have been widely applied medically since the first report of BoNTs for ocular strabismus in 1980 \[[@B10-toxins-08-00201],[@B11-toxins-08-00201]\]. BoNT serotype A (BoNT-A) is the most widely used clinically, it can inhibit the release of neurotransmitters from nerve fibers and the urothelium \[[@B12-toxins-08-00201],[@B13-toxins-08-00201],[@B14-toxins-08-00201]\]. Dykstra et al. firstly reported their experience of injections of BoNT-A into the external urethral sphincter to successfully treat detrusor sphincter dyssynergia of spinal cord injury patients \[[@B15-toxins-08-00201]\]. Intravesical BoNT-A injection has been used in patients with BPS/IC since 2004. The pilot study reported that nine (69%) of 13 patients had subjective improvement after BoNT-A treatment \[[@B16-toxins-08-00201]\]. However, recently, Gottsch et al. \[[@B16-toxins-08-00201]\] investigated the efficacy of periurethral injection of 50 IU BoNTA in BPS/IC, and reported non-significant results on the main outcomes when compared with placebo. In the past decade, many studies have shown the efficacy of intravesical BoNT-A in BPS/IC though it has some side effects including urinary tract infection and urinary difficulty, and it seems to be a promising alternative treatment. In this review, we discuss the available mechanism and current medical evidence of BoNT-A for treating BPS/IC.

2. Mechanisms of BoNT-A {#sec2-toxins-08-00201}
=======================

Internalization of BoNT/A begins with binding its \~100 kDa heavy chain to a specific receptor on the membrane of presynaptic neurons in the cholinergic nerve terminal. BoNT/A is then sequestered within a vesicle by endocytosis and undergoes a pH-dependent conformational change, leading to the translocation of its \~50 kDa light chain into the cytosol. After entering the cytosol, the light chain cleaves the SNAP-25 (synaptosome associated protein of molecular weight of 25 kDa), a subset of SNARE (soluble *N*-ethylmaleimide-sensitive fusion attachment protein receptor) proteins which mediate the fusion of the acetylcholine-containing vesicle with the presynaptic membrane. This interaction ultimately disrupts the release of neurotransmitter into the synapse, resulting in flaccid paralysis of the muscle \[[@B17-toxins-08-00201]\]. There have been also several studies showing that BoNT/A inhibits the release of neurotransmitters that regulate pain and inflammation \[[@B18-toxins-08-00201],[@B19-toxins-08-00201],[@B20-toxins-08-00201]\]. In an animal formalin-induced inflammatory pain model, the authors demonstrated the antinociceptive effects of BoNT-A \[[@B21-toxins-08-00201]\]. Substance P and CGRP are neurotransmitters released by mainly C fibers, a primary nociceptive afferents of urinary bladder, Welch et al. found that BoNT can inhibit the release of substance P from cultured embryonic dorsal root ganglia neurons \[[@B22-toxins-08-00201]\]. On the other hand, BoNT/A can diminish the amount of calcitonin gene-related peptide (CGRP) in rat trigeminal ganglia cells \[[@B23-toxins-08-00201]\]. BoNT/A has been found to be able to reduce neurogenic inflammation, which is suggested to be associated with BPS/IC. In a capsaicin-induced prostatitis rat model, BoNT inhibited cyclooxygenase-2 expression \[[@B24-toxins-08-00201]\]. Liu et al. demonstrated that BoNT-A injection to bladder can reduce the urine level of nerve growth factor, which is associated with neurogenic inflammation, by inhibiting the action of interleulkin-1, a proinflammatory cytokine \[[@B25-toxins-08-00201]\]. In addition, BoNT can inhibit the delivery of the transient receptor potential vanilloid 1 (TRPV1) to neuron cell membranes \[[@B26-toxins-08-00201]\].

TRPV1 has been identified to play an important role in the symptoms of urinary urgency, frequency and inflammatory pain in BPS/IC \[[@B27-toxins-08-00201]\]. Liu et al. \[[@B27-toxins-08-00201]\] showed that increased severity of bladder inflammation correlated with a higher expression of TRPV1-immunoreactive nerve fibers in BPS/IC patients' bladders and correlated with clinical symptoms. The number of suburothelial afferents expressing TRPV1 was significantly reduced after BoNT-A treatment. The decreased levels of these sensory receptors are associated with a decreased sensation of urgency \[[@B27-toxins-08-00201]\]. In addition, inhibition of purinergic P2X3 receptors on afferent terminals, which resulted in less ATP release from the urothelium can improve the painful sensations in BPS/IC. Apostolidis et al. analyzed the expression of P2X3 receptors in the bladder biopsy specimen of patients with detrusor overactivity after intradetrusor injection of BoNT-A demonstrated that P2X3-immunoreactive fibers were decreased significantly and the reduction of P2X3 expression significantly correlated with reduction of urgency episodes and urodynamic parameters \[[@B28-toxins-08-00201]\]. Taken together, BoNT-A might improve the underlying neuroregulatory disorders of the urinary bladder in BPS/IC patients.

3. Clinical Evidence of Intravesical BoNT-A for BPS/IC {#sec3-toxins-08-00201}
======================================================

Several studies have supported the efficacy of BoNT-A in BPS/IC.

Smith et al. \[[@B16-toxins-08-00201]\] first demonstrated the results of 200 IU BoNT-A trigonal and bladder base injection in treating BPS/IC in 13 patients and they showed a significant overall reduction in pain scores. Based on the previous study \[[@B29-toxins-08-00201]\], which found most nociceptive bladder afferents are located in the trigone, Pinto et al. \[[@B29-toxins-08-00201]\] performed trigonal injection with 100 IU BoNT-A in 26 women with refractory BPS/IC. The results demonstrated that pelvic pain, daytime and night-time voiding frequency, O'Leary-Sant Interstitial Cystitis Symptom Index (ICSI) and quality of life of all patients improved significantly. The maximal cystometric capacity increased and the efficacy remained in \>50% of the patients for 9 months \[[@B30-toxins-08-00201]\]. Giannantoni et al. \[[@B31-toxins-08-00201]\] analyzed the efficacy of 200 IU suburothelial OnabotulinumtoxinA injection to trigone and bladder floor in 14 patients and they found that 12 patients (85.7%) had improvements in terms of daytime frequency, nocturia, visual analogue scale (VAS) score and increased cystometric capacity. Chung et al. reported their experience of 100 IU suburothelial BoNT-A injection immediately followed by cystoscopic hydrodistention in 67 refractory BPS/IC patients and the ICSI and Interstitial Cystitis Problem Index (ICPI), VAS score for pain, functional bladder capacity, and global response assessment (GRA) were all significantly improved compared to baseline data \[[@B32-toxins-08-00201]\]. In another long term follow-up study in 15 patients, Onabotulinumtoxin-A at 200 IU submucosally injected to the bladder trigone and lateral walls, 13 patients (86.6%) reported subjective improvement regarding the mean VAS score, and daytime and nighttime urinary frequency \[[@B33-toxins-08-00201]\]. However, at one year after treatment, pain recurred in all patients and nine patients suffered from dysuria 1 month after BoNT-A injection. A prospective, randomized study evaluated the responses of 15 patients and 29 received suburothelial injection with 200 IU or 100 IU of BoNT-A followed by cystoscopic hydrodistension 2 weeks later and 23 patients received the cystoscopic hydrodistension without BoNT-A injection \[[@B34-toxins-08-00201]\]. All patients remained on baseline medications of pentosan polysulphate throughout the study and the results showed that intravesical injections of BoNT-A followed by hydrodistension can provide significantly better clinical results than hydrodistension alone with the BPS/IC symptom and VAS score decreased functional bladder capacity and cystometric bladder capacity increased. Among the total 44 patients in the BoNT-A group, 31 (71%) had clinically improvements at 6 months \[[@B34-toxins-08-00201]\]. There was no efficacy difference between different BoNT-A doses treatment groups however the adverse events were more common in the group of 200 IU compared to 100 IU group. In a recent prospective, open labeled, randomized comparative study, patients with refractory BPS/IC received immediate injection or 1-month delayed injection of botulinum toxin type A, the results showed that the response rate was 73.5% at 1 month, 58.8% at 3 months, 38.2% at 6 months and 20.6% at 12 months \[[@B35-toxins-08-00201]\]. Further multivariate analysis suggested that past exposure to hydrodistension more than three times is associated with a better outcome \[[@B35-toxins-08-00201]\]. Another multicenter, randomized, double-blind, placebo-controlled trial in 60 patients with IC/BPS refractory to conventional treatment alsoindicated that hydrodistension plus suburothelial injections of BoNT-A 100 IU can significantly improve the VAS score and increase cystometric bladder capacity at week 8 after treatment. Bladder tissue obtained from 19 BPS/IC patients before BoNT-A injections and hydrodistension expressed significantly higher nerve growth factor (NGF) levels versus controls, and the level decreased after BoNT-A treatment especially in patients who responded clinically \[[@B36-toxins-08-00201]\]. These findings implied that BoNT-A has an effect in reducing neuroplasticity of sensory fibers in the bladder, and supported the hypothesis of BPS/IC partly originated from neurogenic inflammation.

4. Conclusions {#sec4-toxins-08-00201}
==============

Intravesical BoNT-A injection is promising in the treatment of BPS/IC. BoNT-A can relieve pain, urgency and frequency for refractory BPS/IC though the success rates are variable. BoNT-A can also improve the functional bladder capacity and urodynamic parameters. However, there was no randomized placebo-control study to investigate the efficacy and improvement of quality of life of BoNT-A for BPS/IC patients. Further well-designed larger-scale randomized trials with placebo controls are warranted.
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